{"schema_version":"secwatch.filing_event.v1","accession":"0001831283-23-000124","form_type":"8-K","ticker":"LIANY","cik":"0001831283","company_name":"LianBio","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.842064+00:00","generated_at":"2026-06-08T05:25:05.431560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"LianBio Q3 net loss $24M, inks $350M BMS mavacamten deal, strategic review ongoing","bullets":["Net loss of $24.0M in Q3 2023 vs $21.9M loss in Q3 2022; cash $252.2M as of Sep 30, 2023.","Entered agreement with BMS for mavacamten rights in China and other Asian markets for $350M total consideration.","Phase 3 TP-03 for Demodex blepharitis: mite eradication significant (p<0.001), collarette cure not significant (p=0.15); plans NDA filing.","Board initiated comprehensive strategic review in October 2023; update expected first half 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001831283-23-000124","json":"https://secwatch.observer/filing/0001831283-23-000124.json","markdown":"https://secwatch.observer/filing/0001831283-23-000124.md","text":"https://secwatch.observer/filing/0001831283-23-000124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000124/0001831283-23-000124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000124/lian-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:25:05.431560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a5b997691bcc5f2a186f599c5e7fc56338ff524","claim":"LianBio reported the third quarter ended September 30, 2023 results: net income Net loss was $24.0 million for the third quarter of 2023.","evidence_excerpt":"LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000124/0001831283-23-000124-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $24.0 million for the third quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}